Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $37.59.

A number of equities analysts have recently issued reports on the company. Barclays raised their price target on Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. Stephens restated an "equal weight" rating and set a $29.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Piper Sandler upped their price target on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Truist Financial raised their price objective on shares of Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, January 27th. Finally, Wells Fargo & Company cut shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price for the company. in a report on Monday, February 24th.

Insiders Place Their Bets

In other news, CFO Christopher J. Senner sold 29,314 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the transaction, the chief financial officer now owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. The trade was a 3.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 in the last three months. Corporate insiders own 2.85% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB grew its stake in Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 290 shares during the last quarter. Balyasny Asset Management L.P. boosted its holdings in shares of Exelixis by 1.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock valued at $573,000 after buying an additional 317 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock valued at $235,000 after buying an additional 330 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of Exelixis by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after buying an additional 354 shares during the last quarter. Finally, Principal Securities Inc. raised its stake in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Stock Down 0.0 %

Shares of Exelixis stock traded down $0.01 on Friday, reaching $37.71. The company's stock had a trading volume of 2,520,153 shares, compared to its average volume of 2,719,244. The company has a market capitalization of $10.55 billion, a price-to-earnings ratio of 21.31, a P/E/G ratio of 1.13 and a beta of 0.57. The firm's fifty day simple moving average is $35.66 and its two-hundred day simple moving average is $33.00. Exelixis has a 52 week low of $20.14 and a 52 week high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts predict that Exelixis will post 2.04 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.